News

ODU hires Associate VP for Innovation & Commercialization

Kevin Leslie will be Old Dominion University’s first associate vice president for innovation and commercialization, the Norfolk-based university announced Friday.

Leslie will improve ODU’s technology transfer operation to better identify, develop and market faculty, staff and student intellectual property and startups. He also will lead federal and other grant applications related to innovation and ecosystem building.

“Dr. Leslie will take ODU’s innovation and commercialization activities to the next level of success, as appropriate for an R1 institution,” Morris Foster, ODU vice president for research, said in a statement. “ODU will expand its role as Hampton Roads’ academic research and innovation leader.”

For the past two years, Leslie has served as the inaugural executive director of the Hampton Roads Biomedical Research Consortium, a state-sponsored partnership between ODU, Eastern Virginia Medical School, Norfolk State University and Sentara Healthcare to advance regional health equity and bio-health innovation. He worked with regional leadership to deploy $22 million in capital and operating funds, develop and implement strategic plans and build shared research infrastructure and resources.

“Building the Hampton Roads Biomedical Research Consortium helped me gain a deep understanding of the region and its institutions,” Leslie said in a statement. “As ODU’s role in Hampton Roads and the commonwealth continues to grow, I look forward to building on that knowledge to accelerate the translation of ideas from its labs and classrooms out into the world.”

Before leading the HRBRC, Leslie was associate director of Virginia Commonwealth University Ventures and helped lead Richmond’s Health Innovation Consortium, a public-private platform to support novel health care technologies.

Leslie holds bachelor’s and master’s degrees in biology from William & Mary. He has a doctorate in integrated life sciences from VCU.

He is a member of the Civic Leadership Institute’s 2023 Executive Program class and has served as adjunct faculty for the National Science Foundation Innovation Corps (I-Corps) program.

In his role, Leslie will work closely with Sarah Jane Kirkland, who ODU named associate vice president for corporate partnerships in December 2022.

 

Learn more here.

Recent News

10/28/2026

Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a biopharmaceutical company developing treatments for serious inflammatory diseases, today announced that it has changed its corporate name to Azora Therapeutics, Inc. The company’s common stock is expected to commence trading on The Nasdaq Capital Market under the new ticker symbol “AZR” on October 29, 2026. Azora has also launched …

10/28/2026

U.S. Bioscience Industry Powers Over $3 Trillion in Economic Output, New Report Finds

Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry’s economic impact. The report, “The U.S. Bioscience Economy: Advancing Innovation and Strengthening States and Regions,” examines the industry’s economic footprint through employment, wages, business establishments, university research and development, access …

10/26/2026

ATCC Selected by ARPA-H to Support Next-Generation BioStabilization Technologies

ATCC has been selected by the Advanced Research Projects Agency for Health (ARPA-H) as an affiliate to provide independent verification and validation (IV&V) for its BioStabilization Systems (BoSS) program. Through this program, BoSS is taking the “200-degree leap,” from -196°C toward room temperature, to make life-saving cell therapies as easy to store and ship as …